



May 11, 2026

<b>The Manager (CRD)</b> The BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001	<b>The Manager – Listing Department</b> National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai - 400 051
<b>Scrip Code: 530117</b>	<b>Symbol: PRIVISCL</b>

Dear Sir,

**Sub: Outcome of the Board Meeting held today i.e. Monday, May 11, 2026, pursuant to Regulation 30 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulations 30, 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("Listing Regulations") we wish to inform that the Board of Directors of the Company at their meeting held today i.e. Monday, May 11, 2026, has *inter alia* considered and approved the following matters:

1. Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31, 2026.

In terms of Regulation 33, we hereby enclose the following as **Annexure - I**:

- a. The Audit Report on Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026, issued by the Statutory Auditors of the Company;
  - b. Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026;
  - c. Statement of Assets and Liabilities as at March 31, 2026 and Cash Flow Statement for the financial year ended March 31, 2026;
  - d. Declaration by Mr. Mahesh Purshottam Babani (DIN:00051162), Chairman and Managing Director of the Company with respect to Unmodified Opinion on Audited Standalone and Consolidated Financial Results.
2. Recommendation of **Final Dividend of Rs. 10/- (100%) per Equity Share of Rs. 10/- each for the financial year 2025-26**, subject to approval of the shareholders of the Company at the ensuing 41<sup>st</sup> Annual General Meeting of the Company.
  3. Re-appointment of Mr. Bhaktavatsala Rao Doppalapudi (DIN: 00356218), as an Executive Director (Whole-time Director) of the Company for the period of 3 years w.e.f. August 13, 2026, to August 12, 2029, subject to approval of the shareholders of the Company at the ensuing 41<sup>st</sup> Annual General Meeting of the Company.



## PRIVI SPECIALITY CHEMICALS LIMITED

**Knowledge Centre & Regd. Office :** Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710. India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045  
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privi.com | CIN: L15140MH1985PLC286828





Further, the detailed disclosure as required under Regulation 30 of Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure - II**.

4. Re-appointment of M/s. Aneja Associates, Chartered Accountants as the Internal Auditor of the Company for the Financial Year 2026-27.
5. Re-appointment of M/s Kishore Bhatia & Associates, (Firm Registration Number 00294 & ICMA M. No. 8241), as the Cost Auditors of the Company for the Financial Year 2026-27.

Further, the detailed disclosure for points 4 and 5 as required under Regulation 30 of Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith as **Annexure - III**.

6. The 41<sup>st</sup> Annual General Meeting of the Shareholders of the Company will be held on Friday, August 07, 2026.
7. The Record date is fixed as Friday, July 31, 2026, for determining the entitlement of shareholders to receive the dividend for financial year ended March 31, 2026. The Dividend, if approved by the Shareholders at the 41<sup>st</sup> Annual General Meeting, will be paid within 30 days from the date of 41<sup>st</sup> Annual General Meeting.
8. The date of closure of Register of Members and Share Transfers Book of the Company from Saturday, August 01, 2026 to Friday, August 07, 2026 (both days inclusive) for the purpose of holding 41<sup>st</sup> Annual General Meeting of the Company.

The meeting of the Board of Directors commenced at 11:45 a.m. and concluded at 13:55 p.m.

Kindly take the above on record.

Thanking You,

Yours Faithfully,  
For **Privi Speciality Chemicals Limited**

**Ashwini Saumil Shah**  
Company Secretary and Compliance Officer  
Membership No.: A58378



**Encl: As above**



## **PRIVI SPECIALITY CHEMICALS LIMITED**

**Knowledge Centre & Regd. Office** : Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045  
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privi.com | CIN: L15140MH1985PLC286828



## ANNEXURE - I

### AUDITED FINANCIAL RESULTS (CONSOLIDATED & STANDALONE)



## PRIVI SPECIALITY CHEMICALS LIMITED

**Knowledge Centre & Regd. Office :** Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710. India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045  
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privichem.com | CIN: L15140MH1985PLC286828

## Independent Auditor's Report

### To the Board of Directors of Privi Speciality Chemicals Limited

### Report on the audit of the Standalone Annual Financial Results

#### Opinion

We have audited the accompanying standalone annual financial results of Privi Speciality Chemicals Limited (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

#### Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and

## Independent Auditor's Report (Continued)

### Privi Speciality Chemicals Limited

presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



**Independent Auditor's Report (Continued)**  
**Privi Speciality Chemicals Limited**

**Other Matter**

- a. The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248WW-100022



**Jayesh T. Thakkar**

*Partner*

Mumbai

11 May 2026

Membership No.: 113959

UDIN:26113959NDLQEN8197





**Privi Speciality Chemicals Limited**

Regd. Office : Privi House, A-71, TTC Industrial Area, Thane Belapur Road, Kopar Khairane, Navi Mumbai - 400 710, India

Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com

CIN : L15140MH1985PLC286828

Audited standalone statement of assets and liabilities as at March 31, 2026

( Rs. In Lakhs )

Particulars	As at March 31, 2026	As at March 31, 2025
	Audited	Audited
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	95,848.10	93,563.23
Capital work-in-progress	21,740.42	5,628.57
Right of use assets	4,035.95	3,407.56
Other Intangible assets	641.50	930.42
Intangible assets under development	1,611.82	1,386.82
<b>Financial assets</b>		
Investments	8,727.93	6,170.54
Other financial assets	1,903.44	1,808.64
Income tax assets (net)	656.33	1,512.94
Other non-current assets	3,841.50	3,544.22
<b>Total non-current assets</b>	<b>1,39,006.99</b>	<b>1,17,952.94</b>
<b>Current assets</b>		
Inventories	73,509.46	72,267.11
<b>Financial assets</b>		
Investments	2,505.27	-
Trade receivables	58,643.84	40,076.14
Cash and cash equivalents	3,398.81	4,058.45
Bank balances other than cash and cash equivalents	7.22	6.79
Other financial assets	246.59	629.74
Other current assets	10,991.69	12,352.44
<b>Total current assets</b>	<b>1,49,302.88</b>	<b>1,29,390.67</b>
<b>Total assets</b>	<b>2,88,309.87</b>	<b>2,47,343.61</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Equity share capital	3,906.27	3,906.27
Other equity	1,39,857.88	1,06,213.00
<b>Total equity</b>	<b>1,43,764.15</b>	<b>1,10,119.27</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
Borrowings	34,590.46	27,913.38
Lease liabilities	37.51	274.12
Provisions	3,138.17	2,254.17
Deferred tax liabilities (net)	1,945.40	2,221.95
<b>Total non-current liabilities</b>	<b>39,711.54</b>	<b>32,663.62</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
Borrowings	37,882.61	56,862.93
Lease liabilities	342.90	542.84
Trade payables		
a) Total outstanding dues of micro enterprises and small enterprises	835.08	1,243.11
b) Total outstanding dues of creditors other than micro enterprises and small enterprises	54,387.42	39,269.08
Other financial liabilities	10,207.36	6,045.94
Other current liabilities	846.38	316.42
Provisions	332.43	280.40
Current tax liabilities (net)	-	-
<b>Total current liabilities</b>	<b>1,04,834.18</b>	<b>1,04,560.72</b>
<b>Total liabilities</b>	<b>1,44,545.72</b>	<b>1,37,224.34</b>
<b>Total equity and liabilities</b>	<b>2,88,309.87</b>	<b>2,47,343.61</b>



MM

**Privi Speciality Chemicals Limited**

Regd. Office : Privi House, A-71, TTC Industrial Area, Thane Belapur Road, Kopar Khairane, Navi Mumbai - 400 710, India

Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com

CIN : L15140MH1985PLC286828

**Statement of audited standalone financial results for the quarter and year ended March 31, 2026**

(Rs. In lakhs)

Sr. No.	Particulars	Quarter ended March 31, 2026 (Note no.5)	Quarter ended December 31, 2025	Quarter ended March 31, 2025 (Note no.5)	Year ended March 31, 2026	Year ended March 31, 2025
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue from operations	66,034.73	57,252.36	58,072.85	2,45,553.47	2,03,834.26
2	Other income	286.21	626.30	1,417.08	1,688.39	1,790.47
3	<b>Total income (1+2)</b>	<b>66,320.94</b>	<b>57,878.66</b>	<b>59,489.93</b>	<b>2,47,241.86</b>	<b>2,05,624.73</b>
4	<b>Expenses</b>					
	(a) Cost of materials consumed	32,652.05	29,009.58	30,349.39	1,25,787.35	1,14,132.73
	(b) Changes in inventories of finished goods and work-in-progress	2,673.44	(1,371.08)	1,883.30	(1,793.94)	(3,574.49)
	(c) Employee benefits expense	2,131.21	2,783.61	1,944.06	9,507.76	7,515.05
	(d) Finance costs	1,451.07	1,468.86	2,137.31	6,683.82	8,379.31
	(e) Depreciation and amortisation expense	3,295.98	3,215.06	3,177.72	13,020.93	12,667.94
	(f) Power and fuel expense	4,435.45	4,255.37	3,798.44	16,802.80	15,183.00
	(g) Other expenses	5,897.09	7,046.85	7,375.13	29,334.52	25,934.28
	<b>Total expenses (4)</b>	<b>52,536.29</b>	<b>46,408.25</b>	<b>50,665.35</b>	<b>1,99,343.24</b>	<b>1,80,237.82</b>
5	<b>Profit before tax (3-4)</b>	<b>13,784.65</b>	<b>11,470.41</b>	<b>8,824.58</b>	<b>47,898.62</b>	<b>25,386.91</b>
6	<b>Tax expenses</b>					
	Current tax	3,448.55	2,947.35	2,358.79	12,381.28	6,563.27
	Deferred tax (Credit) / Charge	64.26	(45.88)	(146.50)	(226.85)	(106.61)
7	<b>Net profit for the period / year (5-6)</b>	<b>10,271.84</b>	<b>8,568.94</b>	<b>6,612.29</b>	<b>35,744.19</b>	<b>18,930.25</b>
8	<b>Other comprehensive income</b>					
	(i) Items that will not be reclassified to profit or loss					
	-Remeasurements of the net defined benefit plans	70.38	(124.61)	(54.75)	(195.87)	(104.08)
	-Income tax related to above	(17.75)	31.54	13.83	49.70	26.47
	<b>Total other comprehensive (loss) (8)</b>	<b>52.63</b>	<b>(93.07)</b>	<b>(40.92)</b>	<b>(146.17)</b>	<b>(77.61)</b>
9	<b>Total comprehensive income (7+8)</b>	<b>10,324.47</b>	<b>8,475.87</b>	<b>6,571.37</b>	<b>35,598.02</b>	<b>18,852.64</b>
10	Paid up equity share capital (Face value of Rs. 10/- each)	3,906.27	3,906.27	3,906.27	3,906.27	3,906.27
11	Other equity				1,39,857.88	1,06,213.00
12	Earnings per share (EPS) of Rs. 10/- each (*not annualised) (In Rs.) Basic and Diluted (In Rs.)	*26.30	*21.94	*16.93	91.50	48.46

Please see accompanying notes to the audited standalone financial results.







**Privi Speciality Chemicals Limited**


Regd. Office : Privi House, A-71, TTC Industrial Area, Thane Belapur Road, Kopar Khairane, Navi Mumbai - 400 710, India  
 Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com  
 CIN : L15140MH1985PLC286828

Audited standalone statement of cash flows for the year ended March 31, 2026

(Rs. In lakhs)

Sr No.	Particulars	Year ended March 31, 2026	Year ended March 31, 2025
		Audited	Audited
<b>A</b>	<b>Cash flows from operating activities</b>		
	Profit before tax	47,898.62	25,386.91
	Adjustment for:		
	Depreciation and amortisation expenses	12,662.73	12,298.19
	Amortisation of right of use assets	358.20	369.75
	(Gain) on write-back of financial liabilities	(45.77)	(54.92)
	Sundry balances written off	8.59	11.53
	Unrealised foreign exchange (gain) / loss (net)	1,258.79	1,963.92
	Fair value (gain) on Investments	(5.27)	-
	Interest income	(10.71)	(14.08)
	Finance costs	6,683.82	8,379.31
	Loss on sale of property, plant and equipment	4.27	18.53
	(Gain) on disposal of Other Intangible assets	-	(63.78)
	(Gain) on sale of investments (net)	(3.53)	(1.01)
	Allowance for expected credit loss and credit impairment	-	41.20
	<b>Operating cash flows before working capital changes</b>	<b>68,809.74</b>	<b>48,335.55</b>
	Changes in working capital:		
	(Increase) in trade receivables	(18,567.70)	(4,009.07)
	(Increase) in inventories	(1,242.35)	(11,984.55)
	Decrease/(Increase) in other current and non current assets (non financial assets)	1,853.78	(6,556.61)
	Decrease in financial assets	288.35	(781.82)
	Increase / (Decrease) in trade payables	14,710.31	12,175.77
	Increase / (Decrease) in financial liabilities	335.05	36.45
	Increase / (Decrease) in non financial liabilities and provisions	1,265.46	219.89
		<b>(1,357.10)</b>	<b>(10,899.94)</b>
	<b>Cash generated from operating activities</b>	<b>67,452.64</b>	<b>37,435.61</b>
	Income taxes paid	(11,524.67)	(7,031.04)
	<b>Net cash generated from operating activities [A]</b>	<b>55,927.97</b>	<b>30,404.57</b>
<b>B</b>	<b>Cash flows from investing activities</b>		
	Purchase of property, plant and equipment including CWIP, intangible assets, intangible assets under development and capital advances, net of capital creditors	(30,361.19)	(15,127.05)
	Proceeds from sales of property, plant & equipment and Other Intangible assets	0.85	344.96
	Investment in subsidiaries	(2,550.00)	-
	Investment in mutual fund	(2,505.27)	-
	Fixed deposit placed	(5.76)	-
	Proceeds on maturity of Fixed deposit	-	356.72
	Interest received	6.90	14.08
	<b>Net cash (used in) investing activities [B]</b>	<b>(35,414.47)</b>	<b>(14,411.29)</b>
<b>C</b>	<b>Cash flows from financing activities</b>		
	Proceeds from Non-current borrowings	17,390.00	14,900.00
	Repayment of Non-current borrowings	(13,417.40)	(25,716.76)
	Current borrowings (net)	(16,217.75)	6,771.79
	Payment of lease liabilities including interest on lease	(489.69)	(463.26)
	Dividend paid	(1,953.14)	(781.25)
	Finance cost paid	(6,484.71)	(8,220.11)
	<b>Net cash (used in) financing activities [C]</b>	<b>(21,172.69)</b>	<b>(13,509.59)</b>
	<b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>	<b>(659.19)</b>	<b>2,483.69</b>
	<b>Cash and cash equivalents at the beginning of the year</b>	<b>4,058.45</b>	<b>1,575.08</b>
	Exchange differences on translation of foreign currency cash and cash equivalents	(0.45)	(0.32)
	<b>Cash and cash equivalents at the end of the year</b>	<b>3,398.81</b>	<b>4,058.45</b>

Note A : The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.



*Handwritten signature*



**Notes:**

- 1 The audited standalone financial results for the quarter and year ended March 31, 2026 were reviewed by the audit committee and approved by the Board of Directors of Privi Speciality Chemicals Limited ("the Company") at its meeting held on May 11, 2026. The above results have been subjected to audit by the statutory auditors of the Company. The statutory auditors have expressed an unmodified audit opinion.
- 2 The audited standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3 The Company's business activity falls within a single segment viz. 'Aroma Chemical'. There is single operating segment as per Ind AS 108 - "operating segment".
- 4 The Board of Directors at its meeting held on May 11, 2026 has recommended a final dividend of Rs. 10/- per equity share of face value of Rs.10/- each aggregating to Rs.3,906.27 lakhs for the financial year ended March 31, 2026, subject to approval of the shareholders at the ensuing 41<sup>st</sup> annual general meeting of the company.
- 5 The figures for the quarter ended March 31, 2026 and March 31, 2025, were arrived at as difference between audited figures in respect of the financial year and the unaudited figures upto nine months of the relevant financial year.
- 6 The financial results of the Company are available for investors at [www.privi.com](http://www.privi.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

Place: Navi Mumbai  
Date : May 11, 2026



For and on behalf of the Board of Directors  
Privi Speciality Chemicals Limited

  
Mahesh Babani  
Chairman & Managing Director  
DIN: 00051162

## Independent Auditor's Report

### To the Board of Directors of Privi Speciality Chemicals Limited Report on the audit of the Consolidated Annual Financial Results

#### Opinion

We have audited the accompanying consolidated annual financial results of Privi Speciality Chemicals Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditor on financial results of the subsidiaries, the aforesaid consolidated annual financial results:

- a. include the annual financial results of the entities mentioned in Annexure I to the aforesaid consolidated annual financial results.
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2026.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditor referred to in sub paragraph no. (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

#### Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting

## Independent Auditor's Report (Continued)

### Privi Speciality Chemicals Limited

principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

#### Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the





**Independent Auditor's Report (Continued)**  
**Privi Speciality Chemicals Limited**

underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial results of such entities included in the consolidated annual financial results of which we are the independent auditor. For the other entities included in the consolidated annual financial results, which have been audited by other auditor, such other auditor remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matter" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

**Other Matter**

- a. The consolidated annual financial results include the audited financial results of 3 subsidiaries, whose financial results reflects total assets (before consolidation adjustments) of Rs. 58,654.18 lakhs as at 31 March 2026, total revenue (before consolidation adjustments) of Rs. 63,081.82 lakhs and total net loss after tax (before consolidation adjustments) of Rs. 3,586.43 lakhs and cash inflows (before consolidation adjustments) of Rs 92.69 lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditor. The independent auditor's reports on financial results of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditor and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditor.

- b. The consolidated annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which





B S R & Co. LLP

**Independent Auditor's Report (Continued)**  
**Privi Speciality Chemicals Limited**

were subject to limited review by us.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248WW-100022



**Jayesh T Thakkar**

*Partner*

Mumbai

11 May 2026

Membership No.: 113959

UDIN:26113959LLMWPE9340

**Independent Auditor's Report (Continued)**  
**Privi Speciality Chemicals Limited**

**Annexure I**

List of entities included in consolidated annual financial results.

Sr. No	Name of component	Relationship
1	Privi Speciality Chemicals Limited	Holding Company
2	Privi Biotechnologies Private Limited	Wholly Owned Subsidiary
3	Privi Speciality Chemicals USA Corporation	Wholly Owned Subsidiary
4	Prigiv Specialties Private Limited	Subsidiary



**Privi Speciality Chemicals Limited**

Regd. Office : Privi House, A-71, TTC Industrial Area, Thane Belapur Road, Kopar Khairane, Navi Mumbai - 400 710, India

Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com

CIN : L15140MH1985PLC286828

Audited consolidated statement of assets and liabilities as at March 31, 2026

(Rs. In Lakhs)

Particulars	As at March 31, 2026	As at March 31, 2025
	Audited	Audited
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	1,11,168.34	1,09,788.80
Capital work-in-progress	29,764.82	12,747.22
Right of use assets	4,938.23	4,748.55
Other Intangible assets	744.28	1,064.28
Intangible assets under development	1,611.82	1,386.82
Financial assets		
Investments	90.62	83.23
Other financial assets	2,272.58	5,425.83
Income tax assets (net)	756.65	1,535.47
Other non-current assets	6,043.91	5,940.83
<b>Total non-current assets</b>	<b>1,57,391.25</b>	<b>1,42,721.03</b>
<b>Current assets</b>		
Inventories	82,607.11	78,844.58
Financial assets		
Investments	5,358.96	754.01
Trade receivables	52,600.58	39,414.59
Cash and cash equivalents	4,409.45	4,976.40
Bank balances other than cash and cash equivalents	2,543.57	42.71
Other financial assets	147.27	136.01
Other current assets	11,923.82	12,161.29
<b>Total Current Assets</b>	<b>1,59,590.76</b>	<b>1,36,329.59</b>
<b>Total assets</b>	<b>3,16,982.01</b>	<b>2,79,050.62</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Equity share capital	3,906.27	3,906.27
Other equity - Equity attributable to owners of the company	1,37,337.16	1,06,436.75
<b>Equity attributable to shareholders of the Company</b>	<b>1,41,243.43</b>	<b>1,10,343.02</b>
Non-controlling interest	2,817.48	1,449.11
<b>Total equity</b>	<b>1,44,060.91</b>	<b>1,11,792.13</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
Borrowings	57,790.46	51,113.38
Lease liabilities	269.87	946.45
Provisions	3,322.89	2,450.86
Deferred tax liabilities (net)	2,268.78	2,411.30
<b>Total non-current liabilities</b>	<b>63,652.00</b>	<b>56,921.99</b>
<b>Current liabilities</b>		
Financial liabilities		
Borrowings	43,198.83	61,155.79
Lease liabilities	867.57	1,067.51
Trade payables		
a) Total outstanding dues of micro enterprises and small enterprises	835.08	1,243.11
b) Total outstanding dues of creditors other than micro enterprises and small enterprises	51,906.49	38,981.95
Other financial liabilities	10,301.57	6,707.68
Other current liabilities	1,490.15	552.69
Provisions	366.05	294.84
Current tax liabilities (net)	303.36	332.93
<b>Total current liabilities</b>	<b>1,09,269.10</b>	<b>1,10,336.50</b>
<b>Total liabilities</b>	<b>1,72,921.10</b>	<b>1,67,258.49</b>
<b>Total equity and liabilities</b>	<b>3,16,982.01</b>	<b>2,79,050.62</b>





Privi Speciality Chemicals Limited  
 Regd. Office : Privi House, A-71, TTC Industrial Area, Thane Belapur Road, Kopar Khairane, Navi Mumbai-400 710, India  
 Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privico.com  
 CIN : L15140MH1985PLC286828

Statement of audited consolidated financial results for the quarter and year ended March 31, 2026

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter ended March 31, 2026 (Note no.6)	Quarter ended December 31, 2025	Quarter ended March 31, 2025 (Note no.6)	Year ended March 31, 2026	Year ended March 31, 2025
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue from operations	72,151.78	60,464.10	61,355.03	2,56,368.55	2,10,119.09
2	Other income	417.73	650.51	1,481.85	1,923.55	2,064.56
3	<b>Total income (1+2)</b>	<b>72,569.51</b>	<b>61,114.61</b>	<b>62,836.88</b>	<b>2,58,292.10</b>	<b>2,12,183.65</b>
4	<b>Expenses</b>					
	(a) Cost of materials consumed	35,797.63	32,024.33	31,865.77	1,35,565.28	1,17,195.15
	(b) Purchase of stock in trade	1.69	1.58	1.20	155.20	148.64
	(c) Changes in inventories of finished goods, stock in trade and work in progress	4,763.17	(1,834.82)	2,181.88	(4,010.76)	(4,194.61)
	(d) Employee benefits expense	2,511.44	3,318.74	2,354.26	11,471.22	8,651.13
	(e) Finance cost	1,824.85	1,856.96	2,257.09	8,195.35	8,788.33
	(f) Depreciation and amortisation expense	3,648.43	3,550.71	3,491.75	14,379.85	13,175.33
	(g) Power and fuel expense	4,528.03	4,403.29	3,894.23	17,369.19	15,327.37
	(h) Other expenses	6,526.10	7,416.79	7,797.63	31,196.57	27,640.03
	<b>Total expenses (4)</b>	<b>59,601.34</b>	<b>50,737.58</b>	<b>53,843.81</b>	<b>2,14,321.90</b>	<b>1,86,731.37</b>
5	<b>Profit before tax (3-4)</b>	<b>12,968.17</b>	<b>10,377.03</b>	<b>8,993.07</b>	<b>43,970.20</b>	<b>25,452.28</b>
6	<b>Tax expense</b>					
	Current tax	3,450.20	2,895.48	2,520.09	12,382.93	6,857.89
	Deferred tax (credit) / charge	107.41	(3.86)	75.06	(84.83)	119.36
7	<b>Net profit for the periods / year (5-6)</b>	<b>9,410.56</b>	<b>7,485.41</b>	<b>6,397.92</b>	<b>31,672.10</b>	<b>18,475.03</b>
	<b>Attributable to :</b>					
	Owners of the Holding Company	9,369.97	7,799.32	6,652.46	32,753.73	18,699.60
	Non-controlling interest	40.59	(313.91)	(254.54)	(1,081.63)	(224.57)
8	<b>Other comprehensive income</b>					
	(i) Items that will not be reclassified to profit or loss					
	-Remeasurements of the net defined benefit plans	64.32	(126.03)	(55.90)	(205.66)	(108.69)
	-Income tax related to above	(16.23)	31.90	14.12	52.16	27.63
	(ii) Items that will be reclassified to profit or loss					
	-Exchange differences in translating financial statements of foreign operations	107.25	15.12	1.24	253.32	66.76
	-Income tax related to above	-	-	-	-	-
	<b>Total other comprehensive income/(loss) (8)</b>	<b>155.34</b>	<b>(79.01)</b>	<b>(40.54)</b>	<b>99.82</b>	<b>(14.30)</b>
	<b>Attributable to :-</b>					
	Owners of the Holding Company	155.34	(79.01)	(40.54)	99.82	(14.30)
	Non-controlling interest	-	-	-	-	-
9	<b>Total comprehensive income (7+8)</b>	<b>9,565.90</b>	<b>7,406.40</b>	<b>6,357.38</b>	<b>31,771.92</b>	<b>18,460.73</b>
	<b>Attributable to :-</b>					
	Owners of the Holding Company	9,525.31	7,720.31	6,611.92	32,853.55	18,685.30
	Non-controlling interest	40.59	(313.91)	(254.54)	(1,081.63)	(224.57)
10	Paid up equity share capital (Face value of Rs. 10/- each)	3,906.27	3,906.27	3,906.27	3,906.27	3,906.27
11	Other equity				1,37,337.16	1,06,436.75
12	Earnings per share (EPS) of Rs. 10/- each (*not annualised) (In Rs.) Basic and Diluted (In Rs.)	*23.99	*19.97	*17.03	*83.85	47.87

Please see accompanying notes to the audited consolidated financial results.





**Privi Speciality Chemicals Limited**

Regd. Office : Privi House, A-71, TTC Industrial Area, Thane Belapur Road, Kopar Khairane, Navi Mumbai - 400 710, India  
 Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com  
 CIN : L15140MH1985PLC286828

**Audited consolidated statement of cash flows for the year ended March 31, 2026 (Rs. In lakhs)**

Sr No.	Particulars	Year ended March 31, 2026	Year ended March 31, 2025
		Audited	Audited
<b>A</b>	<b>Cash flows from operating activities</b>		
	Profit before tax	43,970.20	25,452.28
	Adjustment for:		
	Depreciation and amortisation expenses	13,582.94	12,720.22
	Amortisation of right of use assets	796.91	455.11
	(Gain) on written-back of financial liabilities	(45.77)	(54.92)
	Sundry balances written off	8.59	11.53
	Unrealised foreign exchange loss (net)	1,149.42	1,963.92
	Interest income	(49.92)	(186.53)
	Finance costs	8,195.35	8,788.33
	Loss on sale of property, plant and equipment (net)	4.27	18.53
	(Gain) on disposal of other intangible assets	-	(63.78)
	(Gain) on sale of investments (net)	(29.52)	(72.24)
	Change in fair value of investments at FVTPL (mutual fund)	(8.96)	(40.85)
	Allowance for expected credit loss and credit impairment	-	41.20
	<b>Operating cash flows before working capital changes</b>	<b>67,573.51</b>	<b>49,032.80</b>
	Changes in working capital:		
	(Increase) in trade receivables	(13,185.99)	(4,705.57)
	(Increase) in inventories	(3,762.53)	(12,906.06)
	Decrease/(Increase) in other current and non current assets (non financial assets)	1,326.98	(8,264.31)
	(Increase) in financial assets	(110.91)	(266.02)
	Increase/ (Decrease) in trade payables	12,516.51	11,973.64
	Increase/ (Decrease) in financial liabilities	341.46	30.15
	Increase in non financial liabilities and provisions	1,943.34	282.15
		<b>(931.14)</b>	<b>(13,856.02)</b>
	<b>Cash generated from operating activities</b>	<b>66,642.37</b>	<b>35,176.78</b>
	Income taxes paid	(11,633.68)	(7,065.74)
	<b>Net cash generated from operating activities [A]</b>	<b>55,008.69</b>	<b>28,111.04</b>
<b>B</b>	<b>Cash flows from investing activities</b>		
	Purchase of property, plant and equipment including CWIP, intangible assets, intangible assets under development and capital advances, net of capital creditors	(32,002.23)	(29,913.72)
	Proceeds from sales of property, plant & equipment and Other Intangible assets	0.85	68.38
	Investment in mutual fund (net)	(5,358.96)	-
	Proceeds from redemption of investments (mutual fund)	754.01	3,201.89
	Fixed deposit placed	-	(3,278.42)
	Proceeds on maturity of Fixed deposit	752.04	339.09
	Interest received	46.11	186.53
	<b>Net cash (used in) investing activities [B]</b>	<b>(35,808.18)</b>	<b>(29,396.25)</b>
<b>C</b>	<b>Cash flows from financing activities</b>		
	Proceeds from Non-current borrowings	11,206.81	31,100.00
	Repayment of Non-current borrowings	(6,984.21)	(25,066.76)
	Current borrowings (net)	(15,502.48)	8,154.61
	Equity contribution received from non controlling interest	2,450.00	-
	Payment of lease liabilities including interest on lease	(1,014.36)	(987.93)
	Dividend paid	(1,953.14)	(781.25)
	Interest paid	(7,969.63)	(8,555.39)
	<b>Net cash (used in) / generated from financing activities [C]</b>	<b>(19,767.01)</b>	<b>3,863.28</b>
	<b>Net (decrease) / increase in cash and cash equivalents (A+B+C)</b>	<b>(566.50)</b>	<b>2,578.07</b>
	<b>Cash and cash equivalents at the beginning of the period</b>	<b>4,976.40</b>	<b>2,398.65</b>
	Exchange differences on translation of foreign currency cash and cash equivalents	(0.45)	(0.32)
	<b>Cash and cash equivalents at the end of the period</b>	<b>4,409.45</b>	<b>4,976.40</b>

Note A : The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.





**Notes:**

- 1 The audited consolidated financial results for the quarter and year ended March 31, 2026 were reviewed by the audit committee and approved by the Board of Directors of Privi Speciality Chemicals Limited ("the Company") at its meeting held on May 11, 2026. These audited consolidated financial results have been subjected to audit by the statutory auditors of the Company. The statutory auditors have expressed an unmodified audit opinion.
- 2 The audited consolidated financial results of Privi Speciality Chemicals Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3 The audited consolidated financial results for the quarter and year ended March 31, 2026 comprise results of the following entities as a group :  
**Name of the Entity**  
Privi Speciality Chemicals Limited  
Privi Biotechnologies Private Limited  
Privi Speciality Chemicals USA Corporation  
Prigiv Specialties Private Limited
- 4 The Group's business activity falls within a single segment viz. 'Aroma Chemical'. There is single operating segment as per Ind AS 108 - "operating segment".
- 5 The Board of Directors at its meeting held on May 11, 2026 has recommended a final dividend of Rs. 10/- per equity share of face value of Rs.10/- each aggregating to Rs.3,906.27 lakhs for the financial year ended March 31, 2026, subject to approval of the shareholders at the ensuing 41<sup>st</sup> annual general meeting of the company.
- 6 The figures for the quarter ended March 31, 2026 and March 31, 2025, were arrived at as difference between audited figures in respect of the financial year and the unaudited figures upto nine months of the relevant financial year.
- 7 The financial results of the Group are available for investors at [www.privi.com](http://www.privi.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

Place: Navi Mumbai  
Date : May 11, 2026



For and on behalf of the Board of Directors  
Privi Speciality Chemicals Limited

  
Mañesh Babani  
Chairman & Managing Director  
DIN: 00051162



## ANNEXURE - I

**DECLARATION BY MR. MAHESH PURSHOTTAM BABANI, (DIN:00051162) CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY WITH RESPECT TO UNMODIFIED OPINION ON FINANCIAL RESULTS**



## PRIVI SPECIALITY CHEMICALS LIMITED

**Knowledge Centre & Regd. Office :** Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045  
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privico.com | CIN: L15140MH1985PLC286828





May 11, 2026

<b>The Manager (CRD)</b> <b>The BSE Limited</b> <b>Phiroze Jeejeebhoy Towers,</b> <b>Dalal Street, Fort,</b> <b>Mumbai- 400001</b>	<b>The Manager – Listing Department</b> <b>National Stock Exchange of India Ltd</b> <b>Exchange Plaza, Plot no. C/1, G Block,</b> <b>Bandra-Kurla Complex, Bandra (East)</b> <b>Mumbai - 400 051</b>
<b>Scrip Code: 530117</b>	<b>Symbol: PRIVISCL</b>

Dear Sir,

**Sub: Declaration of un-modified opinion on Financial Results (Standalone and Consolidated) for the financial year ended March 31, 2026.**

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, I hereby declare that the Statutory Auditors of the Company M/s. BSR & Co. LLP, Chartered Accountants (FRN: 101248W/W-100022) have issued an Audit Report with unmodified opinion in respect of Annual Audited Financial Results of the Company (Standalone & Consolidated) for the year ended March 31, 2026.

Kindly take the above on record and oblige.

Thanking You,

Yours Faithfully,

**For Privi Speciality Chemicals Limited**

**Mahesh Purshottam Babani**  
**Chairman and Managing Director**  
**DIN: 00051162**



## **PRIVI SPECIALITY CHEMICALS LIMITED**

**Knowledge Centre & Regd. Office :** Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045  
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privi.com | CIN: L15140MH1985PLC286828



## ANNEXURE - II

**DISCLOSURE AS REQUIRED UNDER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR NO. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 DATED JANUARY 30, 2026 ARE AS FOLLOWS:**

**Re-appointment of Mr. Bhaktavatsala Rao Doppalapudi (DIN: 00356218) as an Executive Director (Whole-time director) of the Company**

Sr. No.	Particulars	Disclosures
1	Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment of Mr. Bhaktavatsala Rao Doppalapudi as the Executive Director (Whole-time Director) of the Company upon completion of his existing tenure of three years
2	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/re-appointment	Re-appointment with effect from August 13, 2026  Terms of re-appointment: Re-appointed for a period of 3 (three) consecutive years commencing from August 13, 2026 upto August 12, 2029 (both days inclusive), subject to approval of the shareholders of the Company.
3	Brief Profile (in case of appointment)	Mr. Bhaktavatsala Rao Doppalapudi has been associated with Privi group since 1982. Mr. Rao oversees Operations, Research & Development, Personnel and raw material sourcing. Mr. Rao has worked diligently in converting the vision of the Company to reality and has handled various projects right from their conception to completion. He has been instrumental in putting up the manufacturing facilities in a swift and cost-effective manner and chartering the growth of the Company. His vast experience, in depth knowledge of chemicals and engineering has helped PRIVI to attain the current position. He takes keen interest in R & D activities of the Company, especially in developing green technologies. He is involved in the operations of the company and institutionalizing various processes in the management of the company.  Mr. Rao is the Managing Director of Privi Biotechnologies Private Limited, the wholly owned Subsidiary of the Company. Mr. Rao is a post-graduate in Engineering with over 39 years' experience.
4	Disclosure of relationships between Directors (in case of appointment of the Director)	Mr. Bhaktavatsala Rao Doppalapudi is not related to any other Director of the Company.



## PRIVI SPECIALITY CHEMICALS LIMITED

**Knowledge Centre & Regd. Office :** Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045  
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privicom | CIN: L15140MH1985PLC286828





5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and National Stock Exchange of India with ref no. NSE/CML/2018/24, dated June 20, 2018	Mr. Bhaktavatsala Rao Doppalapudi is not debarred from holding the office of a director by virtue of any SEBI order or any other such authority
---	--	---



## PRIVI SPECIALITY CHEMICALS LIMITED

**Knowledge Centre & Regd. Office :** Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navimumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045  
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privi.com | CIN: L15140MH1985PLC286828





### ANNEXURE – III

**DISCLOSURE AS REQUIRED UNDER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR NO. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 DATED JANUARY 30, 2026 ARE AS FOLLOWS:**

Particulars	Re-appointment of M/s. Aneja Associates, Chartered Accountants as the Internal Auditor of the Company for the Financial Year 2026-27.	Re-appointment of M/s. Kishore Bhatia & Associates, (Firm Registration Number 00294 & ICMA M. No. 8241), as the Cost Auditors of the Company for the Financial Year 2026-27.
Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment	Re-appointment
Date of appointment/ re-appointment/ cessation (as applicable)	May 11, 2026	May 11, 2026
Term of Appointment/ re-appointment	Appointment as an Internal Auditor of the Company for the Financial Year 2026-27.	Appointment as a Cost Auditor of the Company for the Financial Year 2026-27.
Brief Profile (in case of appointment)	NA	NA
Details of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable



## PRIVI SPECIALITY CHEMICALS LIMITED

Knowledge Centre & Regd. Office : Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710. India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045  
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privic.com | CIN: L15140MH1985PLC286828